US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Intensity Therapeutics, Inc.

7.91

+0.19002.46%

Pre-market: 7.76-0.1519-1.92%09:11 EDT

Volume:19.82K

Turnover:152.28K

Market Cap:20.04M

PE:-0.62

High:7.91

Open:7.79

Low:7.60

Close:7.72

52wk High:62.49

52wk Low:4.63

Shares:2.53M

Float Shares:2.32M

Volume Ratio:0.90

T/O Rate:0.85%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-12.7855

EPS(LYR):-29.2443

ROE:-234.70%

ROA:-101.66%

PB:2.78

PE(LYR):-0.27

Loading ...

Overview Company News Filings

BRIEF-Intensity Therapeutics Granted 180-Day Extension

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance With Nasdaq's Minimum Bid Price Requirement

THOMSON REUTERS

BRIEF-Intensity Therapeutics Files For Offering Of Up To $30 Million Common Stock - SEC Filing

Intensity Therapeutics Unveils New Breast Cancer Therapy Data at 2025 SABCS

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

THOMSON REUTERS

Intensity Therapeutics Inc - Files for Offering of up to $30 Mln Common Stock - SEC Filing

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Curis (CRIS) and Intensity Therapeutics, Inc. (INTS)

Intensity Therapeutics Q3 net loss narrows to $2.7 mln

Intensity Therapeutics reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027

BRIEF-Intensity Therapeutics Q3 Operating Income USD -2.733 Million

Intensity Therapeutics Q3 Basic EPS USD -0.06

THOMSON REUTERS

Intensity Therapeutics Raises $4 Million in Registered Direct Offering

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

THOMSON REUTERS

Intensity Therapeutics Inc - Expects Cash Runway Until End of Q1 2027

THOMSON REUTERS

Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know

Benzinga_recent_news

Positive Phase 1/2 Clinical Data for Cancer Candidate Drug Sends Intensity Therapeutics (INTS.US) Soaring 395%

BUZZ-U.S. STOCKS ON THE MOVE-Fiserv, CMS Energy, Moderna

BUZZ-Intensity Therapeutics shares more than double on promising cancer trial data

Intensity Therapeutics Reports Promising Phase 1/2 Results for INT230-6 in Advanced Solid Tumors

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of Int230-6 for the Treatment of Metastatic or Refractory Cancers in Ebiomedicine, a Lancet Discovery Science Journal

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/INTS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INTS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INTS\",,,,,undefined,":{"symbol":"INTS","market":"US","secType":"STK","nameCN":"Intensity Therapeutics, Inc.","latestPrice":7.91,"timestamp":1773259200000,"preClose":7.72,"halted":0,"volume":19817,"hourTrading":{"tag":"盘前","latestPrice":7.7581,"preClose":7.91,"latestTime":"09:11 EDT","volume":26909,"amount":218357.870302,"timestamp":1773321089803,"change":-0.1519,"changeRate":-0.019204,"amplitude":0.064475},"delay":0,"changeRate":0.024611398963730623,"floatShares":2319200,"shares":2533900,"eps":-12.785525,"marketStatus":"Pre-Mkt","change":0.19,"latestTime":"03-12 09:15:22 EDT","open":7.7924,"high":7.91,"low":7.595,"amount":152278.09856349998,"amplitude":0.040803,"askPrice":8.19,"askSize":42,"bidPrice":7.5,"bidSize":280,"shortable":3,"etf":0,"ttmEps":-12.785525,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773322200000},"marketStatusCode":1,"adr":0,"listingDate":1666324800000,"exchange":"NASDAQ","adjPreClose":7.91,"preHourTrading":{"tag":"盘前","latestPrice":7.7581,"preClose":7.91,"latestTime":"09:11 EDT","volume":26909,"amount":218357.870302,"timestamp":1773321089803,"change":-0.1519,"changeRate":-0.019204,"amplitude":0.064475},"postHourTrading":{"tag":"盘后","latestPrice":7.91,"preClose":7.91,"latestTime":"19:56 EDT","volume":101,"amount":803.9916,"timestamp":1773273417496,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9040932138434433},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INTS\",,,,,undefined,":{"symbol":"INTS","floatShares":2319200,"roa":"-101.66%","roe":"-234.70%","lyrEps":-29.2443,"volumeRatio":0.9040932138434433,"shares":2533900,"dividePrice":0,"high":7.91,"amplitude":0.040803,"preClose":7.72,"low":7.595,"week52Low":4.6325,"pbRate":"2.78","week52High":62.49,"institutionHeld":0,"latestPrice":7.91,"committee":0.73913,"eps":-12.785525,"divideRate":0,"volume":19817,"delay":0,"ttmEps":-12.785525,"open":7.7924,"prevYearClose":10.255,"prevWeekClose":7.95,"prevMonthClose":7.66,"prevQuarterClose":10.255,"fiveDayClose":7.7,"twentyDayClose":9.3625,"sixtyDayClose":14.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INTS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-19","symbol":"INTS","defaultRemindTime":1771511400000,"type":"split","dateTimestamp":1771477200000,"forFactor":25,"toFactor":1,"ratio":25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INTS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INTS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.8333,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1763006400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/INTS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"INTS","date":"2026-03-11","current":-0.618668,"percent":0.772657,"low":-15.25821,"twenty":-6.344023,"median":-2.823464,"eighty":-1.20729,"high":-0.31723,"avg":-3.970225,"sd":3.255341,"marketCap":19561422},"quantilePoints":[{"date":"2022-10-20","current":-9.173693,"twenty":-9.173693,"median":-9.173693,"eighty":-9.173693,"marketCap":80934718},{"date":"2023-07-07","current":-12.000673,"twenty":-12.000673,"median":-11.893737,"eighty":-9.173693,"marketCap":78596262},{"date":"2023-07-14","current":-11.805305,"twenty":-12.014248,"median":-11.893737,"eighty":-11.600651,"marketCap":77316730},{"date":"2023-07-21","current":-12.682867,"twenty":-12.306769,"median":-11.947205,"eighty":-11.660654,"marketCap":83064168},{"date":"2023-07-28","current":-11.867988,"twenty":-12.682867,"median":-12.014248,"eighty":-11.805305,"marketCap":77727261},{"date":"2023-08-04","current":-12.81868,"twenty":-12.682867,"median":-12.066484,"eighty":-11.867988,"marketCap":83953652},{"date":"2023-08-11","current":-12.933599,"twenty":-12.933599,"median":-12.306769,"eighty":-11.888882,"marketCap":84706293},{"date":"2023-08-18","current":-9.652146,"twenty":-12.81868,"median":-12.1197,"eighty":-11.660654,"marketCap":80327292},{"date":"2023-08-25","current":-9.800135,"twenty":-12.808233,"median":-12.000673,"eighty":-9.800135,"marketCap":81558886},{"date":"2023-09-01","current":-9.487714,"twenty":-12.770623,"median":-11.912204,"eighty":-9.783692,"marketCap":78958855},{"date":"2023-09-08","current":-9.093078,"twenty":-12.755579,"median":-11.893737,"eighty":-9.638992,"marketCap":75674604},{"date":"2023-09-15","current":-8.073601,"twenty":-12.70794,"median":-11.836647,"eighty":-9.487714,"marketCap":67190291},{"date":"2023-09-22","current":-6.034647,"twenty":-12.632721,"median":-11.600651,"eighty":-9.000996,"marketCap":50221663},{"date":"2023-09-29","current":-6.626601,"twenty":-12.586753,"median":-9.923459,"eighty":-8.293939,"marketCap":55148039},{"date":"2023-10-06","current":-7.251442,"twenty":-12.570873,"median":-9.800135,"eighty":-7.560574,"marketCap":60348102},{"date":"2023-10-13","current":-6.626601,"twenty":-12.448015,"median":-9.783692,"eighty":-7.192246,"marketCap":55148039},{"date":"2023-10-20","current":-4.636976,"twenty":-12.331842,"median":-9.61926,"eighty":-6.745518,"marketCap":38589943},{"date":"2023-10-23","current":-4.96584,"twenty":-12.319306,"median":-9.578152,"eighty":-6.686849,"marketCap":41326818},{"date":"2023-11-03","current":-4.932954,"twenty":-12.157898,"median":-9.487714,"eighty":-6.567406,"marketCap":41053131},{"date":"2023-11-10","current":-4.609845,"twenty":-12.119112,"median":-9.173693,"eighty":-6.48519,"marketCap":38364150},{"date":"2023-11-17","current":-3.237228,"twenty":-12.035142,"median":-8.862874,"eighty":-6.287872,"marketCap":28737191},{"date":"2023-11-24","current":-3.590621,"twenty":-12.006103,"median":-8.517567,"eighty":-5.189368,"marketCap":31874301},{"date":"2023-12-01","current":-3.784438,"twenty":-11.971208,"median":-8.209257,"eighty":-5.01517,"marketCap":33594828},{"date":"2023-12-08","current":-6.177413,"twenty":-11.939029,"median":-7.613192,"eighty":-5.01517,"marketCap":54837508},{"date":"2023-12-15","current":-12.447487,"twenty":-12.056037,"median":-8.209257,"eighty":-5.034902,"marketCap":110497578},{"date":"2023-12-22","current":-9.544103,"twenty":-12.056037,"median":-8.517567,"eighty":-5.074891,"marketCap":84723949},{"date":"2023-12-29","current":-12.200391,"twenty":-12.097826,"median":-8.854652,"eighty":-5.093498,"marketCap":108304078},{"date":"2024-01-05","current":-12.586479,"twenty":-12.221667,"median":-9.093078,"eighty":-5.095649,"marketCap":111731422},{"date":"2024-01-12","current":-9.080797,"twenty":-12.136622,"median":-9.173576,"eighty":-5.162954,"marketCap":80611136},{"date":"2024-01-19","current":-7.443783,"twenty":-12.119504,"median":-9.086938,"eighty":-5.189368,"marketCap":66079197},{"date":"2024-01-26","current":-6.94959,"twenty":-12.056037,"median":-8.862874,"eighty":-5.265897,"marketCap":61692196},{"date":"2024-02-02","current":-7.706323,"twenty":-12.006103,"median":-8.582973,"eighty":-5.358906,"marketCap":68409791},{"date":"2024-02-09","current":-5.497898,"twenty":-11.971208,"median":-8.279141,"eighty":-5.454656,"marketCap":48805382},{"date":"2024-02-16","current":-4.67939,"twenty":-11.939029,"median":-8.106172,"eighty":-5.189368,"marketCap":41539412},{"date":"2024-02-23","current":-4.63306,"twenty":-11.915897,"median":-7.791263,"eighty":-5.065946,"marketCap":41128131},{"date":"2024-03-01","current":-5.714107,"twenty":-11.893737,"median":-7.613192,"eighty":-5.065946,"marketCap":50724694},{"date":"2024-03-08","current":-8.617491,"twenty":-11.891795,"median":-7.659757,"eighty":-5.094215,"marketCap":76498323},{"date":"2024-03-15","current":-6.42451,"twenty":-11.880524,"median":-7.613192,"eighty":-5.12966,"marketCap":57031008},{"date":"2024-03-22","current":-7.168217,"twenty":-11.842915,"median":-7.462714,"eighty":-5.183371,"marketCap":75538667},{"date":"2024-03-28","current":-6.569781,"twenty":-11.793205,"median":-7.382998,"eighty":-5.190398,"marketCap":69232353},{"date":"2024-04-05","current":-6.062412,"twenty":-11.727976,"median":-7.320234,"eighty":-5.219219,"marketCap":63885696},{"date":"2024-04-12","current":-5.919308,"twenty":-11.648653,"median":-7.270395,"eighty":-5.328019,"marketCap":62377665},{"date":"2024-04-19","current":-4.956607,"twenty":-11.467325,"median":-7.168217,"eighty":-5.219219,"marketCap":52232726},{"date":"2024-04-26","current":-5.106216,"twenty":-10.872247,"median":-7.057617,"eighty":-5.181486,"marketCap":53809304},{"date":"2024-05-03","current":-5.203787,"twenty":-10.575732,"median":-7.004794,"eighty":-5.110119,"marketCap":54837508},{"date":"2024-05-10","current":-4.89156,"twenty":-10.334812,"median":-6.920091,"eighty":-5.07751,"marketCap":51547257},{"date":"2024-05-17","current":-5.064674,"twenty":-10.138832,"median":-6.816961,"eighty":-5.04775,"marketCap":69917822},{"date":"2024-05-24","current":-5.034882,"twenty":-10.040205,"median":-6.769756,"eighty":-5.01517,"marketCap":69506541},{"date":"2024-05-31","current":-4.905782,"twenty":-10.013896,"median":-6.720408,"eighty":-4.982612,"marketCap":67724322},{"date":"2024-06-07","current":-4.945811,"twenty":-9.945635,"median":-6.626601,"eighty":-4.965367,"marketCap":68276920},{"date":"2024-06-14","current":-4.747756,"twenty":-9.859151,"median":-6.577272,"eighty":-4.943699,"marketCap":65542772},{"date":"2024-06-21","current":-4.638498,"twenty":-9.834825,"median":-6.527942,"eighty":-4.905297,"marketCap":64034465},{"date":"2024-06-28","current":-4.887408,"twenty":-9.833021,"median":-6.527942,"eighty":-4.896744,"marketCap":67470661},{"date":"2024-07-05","current":-4.817184,"twenty":-9.806712,"median":-6.504734,"eighty":-4.887289,"marketCap":66501232},{"date":"2024-07-12","current":-4.986137,"twenty":-9.800135,"median":-6.468725,"eighty":-4.878216,"marketCap":68833622},{"date":"2024-07-15","current":-5.055665,"twenty":-9.800135,"median":-6.445726,"eighty":-4.87855,"marketCap":69793453},{"date":"2024-08-02","current":-4.807351,"twenty":-9.796846,"median":-6.435118,"eighty":-4.877213,"marketCap":66365484},{"date":"2024-08-09","current":-4.588835,"twenty":-9.783692,"median":-6.41284,"eighty":-4.86516,"marketCap":63348871},{"date":"2024-08-16","current":-3.955696,"twenty":-9.783692,"median":-6.339457,"eighty":-4.820512,"marketCap":59632119},{"date":"2024-08-23","current":-3.896315,"twenty":-9.757383,"median":-6.270563,"eighty":-4.807351,"marketCap":58736948},{"date":"2024-08-30","current":-3.86434,"twenty":-9.645569,"median":-6.204474,"eighty":-4.781352,"marketCap":58254933},{"date":"2024-09-06","current":-3.910018,"twenty":-9.61926,"median":-6.112191,"eighty":-4.747756,"marketCap":58943526},{"date":"2024-09-13","current":-3.837391,"twenty":-9.544103,"median":-6.034647,"eighty":-4.707926,"marketCap":57848664},{"date":"2024-09-20","current":-3.727307,"twenty":-9.537044,"median":-5.97785,"eighty":-4.668296,"marketCap":56189156},{"date":"2024-09-27","current":-3.316207,"twenty":-9.52866,"median":-5.925812,"eighty":-4.63306,"marketCap":49991822},{"date":"2024-10-04","current":-3.2888,"twenty":-9.487714,"median":-5.784184,"eighty":-4.588835,"marketCap":49578667},{"date":"2024-10-11","current":-3.037299,"twenty":-9.487714,"median":-5.559672,"eighty":-4.472545,"marketCap":45787276},{"date":"2024-10-18","current":-2.923378,"twenty":-9.487714,"median":-5.461423,"eighty":-4.216084,"marketCap":44069926},{"date":"2024-10-25","current":-2.923378,"twenty":-9.26612,"median":-5.333882,"eighty":-3.973967,"marketCap":44069926},{"date":"2024-10-31","current":-2.786345,"twenty":-9.192178,"median":-5.307863,"eighty":-3.960154,"marketCap":42004148},{"date":"2024-11-08","current":-2.941649,"twenty":-9.173693,"median":-5.199834,"eighty":-3.926462,"marketCap":44345363},{"date":"2024-11-15","current":-2.689442,"twenty":-9.173505,"median":-5.189027,"eighty":-3.893574,"marketCap":43725630},{"date":"2024-11-22","current":-2.507825,"twenty":-9.109154,"median":-5.115973,"eighty":-3.863938,"marketCap":40772862},{"date":"2024-11-29","current":-2.717615,"twenty":-9.085709,"median":-5.101291,"eighty":-3.84881,"marketCap":44185701},{"date":"2024-12-06","current":-2.321954,"twenty":-9.052999,"median":-5.073692,"eighty":-3.799491,"marketCap":37752650},{"date":"2024-12-13","current":-1.917562,"twenty":-8.931511,"median":-5.06017,"eighty":-3.723653,"marketCap":31177648},{"date":"2024-12-20","current":-1.857563,"twenty":-8.853008,"median":-5.047673,"eighty":-3.619065,"marketCap":30202120},{"date":"2024-12-27","current":-1.764685,"twenty":-8.767209,"median":-5.021654,"eighty":-3.573099,"marketCap":28692014},{"date":"2025-01-03","current":-1.625368,"twenty":-8.642201,"median":-5.01517,"eighty":-3.513045,"marketCap":26426855},{"date":"2025-01-10","current":-1.838802,"twenty":-8.617491,"median":-5.008645,"eighty":-3.463472,"marketCap":29897078},{"date":"2025-01-17","current":-2.572725,"twenty":-8.517567,"median":-4.984374,"eighty":-3.373331,"marketCap":41829936},{"date":"2025-01-24","current":-2.370715,"twenty":-8.346557,"median":-4.965604,"eighty":-3.310726,"marketCap":38545455},{"date":"2025-01-31","current":-2.053117,"twenty":-8.284074,"median":-4.956607,"eighty":-3.212827,"marketCap":33381630},{"date":"2025-02-07","current":-2.238919,"twenty":-8.253306,"median":-4.940989,"eighty":-3.06772,"marketCap":36402592},{"date":"2025-02-14","current":-2.015957,"twenty":-8.160869,"median":-4.905782,"eighty":-3.026792,"marketCap":32777437},{"date":"2025-02-21","current":-2.043827,"twenty":-8.138995,"median":-4.896744,"eighty":-3.006493,"marketCap":33230582},{"date":"2025-02-28","current":-2.099568,"twenty":-8.099657,"median":-4.889484,"eighty":-2.934341,"marketCap":34136870},{"date":"2025-03-07","current":-2.146018,"twenty":-8.038556,"median":-4.87855,"eighty":-2.919724,"marketCap":34892111},{"date":"2025-03-14","current":-2.159953,"twenty":-8.005927,"median":-4.871913,"eighty":-2.813752,"marketCap":35118683},{"date":"2025-03-21","current":-1.801034,"twenty":-7.907089,"median":-4.866947,"eighty":-2.682321,"marketCap":29299223},{"date":"2025-03-28","current":-1.800101,"twenty":-7.780452,"median":-4.846639,"eighty":-2.622879,"marketCap":29284042},{"date":"2025-04-04","current":-1.82903,"twenty":-7.718678,"median":-4.817184,"eighty":-2.548971,"marketCap":29754652},{"date":"2025-04-11","current":-1.810366,"twenty":-7.669259,"median":-4.807351,"eighty":-2.494707,"marketCap":29451033},{"date":"2025-04-17","current":-1.735712,"twenty":-7.632006,"median":-4.806913,"eighty":-2.414832,"marketCap":28236557},{"date":"2025-04-25","current":-0.839954,"twenty":-7.607202,"median":-4.796544,"eighty":-2.376882,"marketCap":13664368},{"date":"2025-05-02","current":-0.521647,"twenty":-7.551589,"median":-4.752722,"eighty":-2.245719,"marketCap":8486148},{"date":"2025-05-09","current":-0.530045,"twenty":-7.466501,"median":-4.747756,"eighty":-2.177388,"marketCap":8622776},{"date":"2025-05-16","current":-0.505526,"twenty":-7.426042,"median":-4.707976,"eighty":-2.157166,"marketCap":7588954},{"date":"2025-05-23","current":-0.365063,"twenty":-7.386285,"median":-4.686306,"eighty":-2.149257,"marketCap":5480321},{"date":"2025-05-30","current":-0.393378,"twenty":-7.360388,"median":-4.668296,"eighty":-2.119771,"marketCap":5905387},{"date":"2025-06-06","current":-0.549666,"twenty":-7.332589,"median":-4.637737,"eighty":-2.099568,"marketCap":8251593},{"date":"2025-06-13","current":-0.392181,"twenty":-7.316341,"median":-4.63306,"eighty":-2.056833,"marketCap":5887424},{"date":"2025-06-20","current":-0.532797,"twenty":-7.300771,"median":-4.609845,"eighty":-2.053117,"marketCap":7998351},{"date":"2025-06-27","current":-0.511084,"twenty":-7.289347,"median":-4.571286,"eighty":-2.034537,"marketCap":7672399},{"date":"2025-07-03","current":-0.492879,"twenty":-7.259023,"median":-4.506472,"eighty":-1.991406,"marketCap":7399101},{"date":"2025-07-11","current":-0.528288,"twenty":-7.195283,"median":-4.389384,"eighty":-1.94521,"marketCap":7930653},{"date":"2025-07-18","current":-0.557015,"twenty":-7.170822,"median":-4.18175,"eighty":-1.91115,"marketCap":8361912},{"date":"2025-07-25","current":-0.542818,"twenty":-7.116406,"median":-4.001374,"eighty":-1.881987,"marketCap":8148790},{"date":"2025-08-01","current":-0.462648,"twenty":-7.091556,"median":-3.972293,"eighty":-1.853811,"marketCap":6945276},{"date":"2025-08-08","current":-0.502341,"twenty":-7.039039,"median":-3.955696,"eighty":-1.829566,"marketCap":6318446},{"date":"2025-08-15","current":-1.11677,"twenty":-7.015013,"median":-3.928289,"eighty":-1.810366,"marketCap":14046731},{"date":"2025-08-22","current":-1.175134,"twenty":-7.006256,"median":-3.910018,"eighty":-1.798683,"marketCap":14780832},{"date":"2025-08-29","current":-1.08871,"twenty":-6.960631,"median":-3.889463,"eighty":-1.782371,"marketCap":13693798},{"date":"2025-09-05","current":-1.066138,"twenty":-6.940264,"median":-3.868908,"eighty":-1.769697,"marketCap":13409881},{"date":"2025-09-12","current":-0.906383,"twenty":-6.917299,"median":-3.862331,"eighty":-1.745683,"marketCap":11400489},{"date":"2025-09-19","current":-0.936024,"twenty":-6.885877,"median":-3.848353,"eighty":-1.727072,"marketCap":11773310},{"date":"2025-09-26","current":-0.967225,"twenty":-6.839125,"median":-3.809527,"eighty":-1.460474,"marketCap":12165754},{"date":"2025-10-03","current":-1.053027,"twenty":-6.813143,"median":-3.783279,"eighty":-1.137571,"marketCap":13244974},{"date":"2025-10-10","current":-1.237502,"twenty":-6.788993,"median":-3.727307,"eighty":-1.12949,"marketCap":15565298},{"date":"2025-10-17","current":-1.024946,"twenty":-6.76879,"median":-3.686198,"eighty":-1.120137,"marketCap":12891775},{"date":"2025-10-24","current":-0.939534,"twenty":-6.749312,"median":-3.590621,"eighty":-1.104352,"marketCap":11817460},{"date":"2025-10-31","current":-5.148132,"twenty":-6.716708,"median":-3.589534,"eighty":-1.099571,"marketCap":64753209},{"date":"2025-11-07","current":-1.892719,"twenty":-6.656725,"median":-3.544596,"eighty":-1.101463,"marketCap":23806615},{"date":"2025-11-14","current":-2.446921,"twenty":-6.626601,"median":-3.5023,"eighty":-1.103492,"marketCap":28717059},{"date":"2025-11-21","current":-1.944844,"twenty":-6.606869,"median":-3.463472,"eighty":-1.104352,"marketCap":22824686},{"date":"2025-11-28","current":-2.043621,"twenty":-6.587138,"median":-3.425742,"eighty":-1.107316,"marketCap":23983940},{"date":"2025-12-05","current":-2.35582,"twenty":-6.574276,"median":-3.358472,"eighty":-1.113245,"marketCap":27647903},{"date":"2025-12-12","current":-3.019626,"twenty":-6.553045,"median":-3.316207,"eighty":-1.116199,"marketCap":35438329},{"date":"2025-12-19","current":-2.137793,"twenty":-6.527942,"median":-3.243133,"eighty":-1.119015,"marketCap":25089135},{"date":"2025-12-26","current":-2.080983,"twenty":-6.524653,"median":-3.176227,"eighty":-1.123804,"marketCap":24422414},{"date":"2026-01-02","current":-2.099408,"twenty":-6.511499,"median":-3.101522,"eighty":-1.12949,"marketCap":24638648},{"date":"2026-01-09","current":-2.221728,"twenty":-6.504734,"median":-3.060412,"eighty":-1.12949,"marketCap":26074201},{"date":"2026-01-16","current":-2.13984,"twenty":-6.495056,"median":-3.033553,"eighty":-1.130611,"marketCap":25113161},{"date":"2026-01-23","current":-2.069211,"twenty":-6.49239,"median":-3.01718,"eighty":-1.136,"marketCap":24284265},{"date":"2026-01-30","current":-1.919766,"twenty":-6.454926,"median":-3.013363,"eighty":-1.137646,"marketCap":22530368},{"date":"2026-02-06","current":-1.733982,"twenty":-6.428753,"median":-2.969787,"eighty":-1.161067,"marketCap":20350010},{"date":"2026-02-13","current":-1.899293,"twenty":-6.415174,"median":-2.923378,"eighty":-1.169405,"marketCap":22290108},{"date":"2026-02-20","current":-1.407702,"twenty":-6.41284,"median":-2.923378,"eighty":-1.173092,"marketCap":16520786},{"date":"2026-02-27","current":-1.68406,"twenty":-6.373511,"median":-2.907391,"eighty":-1.18307,"marketCap":19764131},{"date":"2026-03-06","current":-1.666788,"twenty":-6.347157,"median":-2.832023,"eighty":-1.198842,"marketCap":19561422},{"date":"2026-03-11","current":-1.666788,"twenty":-6.344023,"median":-2.823464,"eighty":-1.20729,"marketCap":19561422}],"updateTime":1773315348373},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"INTS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589189257","title":"BRIEF-Intensity Therapeutics Granted 180-Day Extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2589189257","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589189257?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:39","pubTimestamp":1764938396,"startTime":"0","endTime":"0","summary":"BRIEF-Intensity Therapeutics Granted 180-Day Extension Dec 5 (Reuters) - Intensity Therapeutics Inc INTS.O:INTENSITY THERAPEUTICS GRANTED 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ'S MINIMUM B","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XA1AN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2589892389","title":"Intensity Therapeutics Granted 180-Day Extension to Regain Compliance With Nasdaq's Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2589892389","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589892389?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:30","pubTimestamp":1764937817,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XA1AN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2588870978","title":"BRIEF-Intensity Therapeutics Files For Offering Of Up To $30 Million Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588870978","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588870978?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:09","pubTimestamp":1764857355,"startTime":"0","endTime":"0","summary":"BRIEF-Intensity Therapeutics Files For Offering Of Up To $30 Million Common Stock - SEC FilingDec 4 (Reuters) - INTENSITY THERAPEUTICS INC - FILES FOR OFFERING OF UP TO $30 MILLION COMMON STOCK - SEC FILINGSource text: [ID:n0001567264-25-000108] ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0N5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2588881015","title":"Intensity Therapeutics Unveils New Breast Cancer Therapy Data at 2025 SABCS","url":"https://stock-news.laohu8.com/highlight/detail?id=2588881015","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588881015?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:47","pubTimestamp":1764852433,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics Inc. announced two upcoming presentations at the 2025 San Antonio Breast Cancer Symposium, scheduled for December 9-12, 2025. The company will present new clinical research, including a study titled \"Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients Hope for Safer, More Effective Breast Cancer Therapy Combinations,\" to be presented by Lewis Bender, M.S. M.A. M.B.A., on December 11, 2025. Another presentation, \"Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: Early observations from INVINCIBLE-4-SAKK 66/22 , a Phase II Randomized Clinical Trial,\" will be presented by Andreas Müller, M.D., on December 12, 2025. The results of these studies will be presented at the symposium.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL21kT80:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2588881024","title":"Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2588881024","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588881024?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:47","pubTimestamp":1764852420,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA5P6J6T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2588088996","title":"Intensity Therapeutics Inc - Files for Offering of up to $30 Mln Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588088996","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588088996?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:03","pubTimestamp":1764849783,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0N5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2583305380","title":"Analysts Offer Insights on Healthcare Companies: Curis (CRIS) and Intensity Therapeutics, Inc. (INTS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583305380","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583305380?lang=en_us&edition=fundamental","pubTime":"2025-11-13 00:00","pubTimestamp":1762963250,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Curis (CRIS – Research Report) and Intensity Therape...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-curis-cris-and-intensity-therapeutics-inc-ints-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-curis-cris-and-intensity-therapeutics-inc-ints-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","INTS","BK4139","LABU","BK4137","BK4588","CRIS","XBI","XLV","HCSG","LU0029874061.USD","BK4585","LU0128526141.USD"],"gpt_icon":0},{"id":"2581434420","title":"Intensity Therapeutics Q3 net loss narrows to $2.7 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2581434420","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581434420?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:36","pubTimestamp":1762465011,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics Q3 net loss narrows to $2.7 mlnOverviewIntensity Therapeutics Q3 net loss narrows to $2.7 mln from $3.5 mln last yearCompany raised $13.6 mln since Q3 start, extending cash runw","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"7026f4aef5369e29e112f6f82189519d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1IM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":1},{"id":"2581501733","title":"Intensity Therapeutics reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2581501733","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581501733?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:03","pubTimestamp":1762463035,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027. Intensity Therapeutics Inc. reported cash and cash equivalents of $7.1 million as of September 30, 2025, with an additional $6.1 million raised in the fourth quarter of 2025, extending the company's cash runway until the end of the first quarter of 2027. Research and development expenses for the third quarter of 2025 were $1.6 million, down from $2.2 million in the same period of 2024, mainly due to reduced clinical trial costs following a pause in the INVINCIBLE-3 Study. The company plans to reinitiate patient enrollment in the INVINCIBLE-4 Study in the first quarter of 2026 after a protocol amendment. No sales or revenue figures were disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"7026f4aef5369e29e112f6f82189519d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL3VdtJV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":1},{"id":"2581012055","title":"BRIEF-Intensity Therapeutics Q3 Operating Income USD -2.733 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581012055","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581012055?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:02","pubTimestamp":1762462965,"startTime":"0","endTime":"0","summary":"BRIEF-Intensity Therapeutics Q3 Operating Income USD -2.733 Million\n\n\nNov 06 (Reuters) - Intensity Therapeutics Q3 basic EPS USD -0.06.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"7026f4aef5369e29e112f6f82189519d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLXCB026D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2581124740","title":"Intensity Therapeutics Q3 Basic EPS USD -0.06","url":"https://stock-news.laohu8.com/highlight/detail?id=2581124740","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581124740?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:02","pubTimestamp":1762462920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"7026f4aef5369e29e112f6f82189519d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLXCB026D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2579469374","title":"Intensity Therapeutics Raises $4 Million in Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2579469374","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579469374?lang=en_us&edition=fundamental","pubTime":"2025-10-31 20:01","pubTimestamp":1761912068,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics, Inc. , a late-stage clinical biotechnology company focused on novel intratumoral cancer therapies, has announced a registered direct offering of its common stock. The company has entered into a securities purchase agreement with a new long-term fundamental investor for the sale of 5,000,000 shares at $0.80 per share, raising gross proceeds of approximately $4 million before expenses. The net proceeds are expected to support advancement of clinical trials, working capital, and general corporate purposes. Upon closing, Intensity Therapeutics anticipates having sufficient cash runway until the end of the first quarter of 2027. A.G.P./Alliance Global Partners is serving as the sole placement agent for the offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL6Cc7Bv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":1},{"id":"2579469818","title":"Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2579469818","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579469818?lang=en_us&edition=fundamental","pubTime":"2025-10-31 20:00","pubTimestamp":1761912003,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nTUA6S1NCM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2579469377","title":"Intensity Therapeutics Inc - Expects Cash Runway Until End of Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2579469377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579469377?lang=en_us&edition=fundamental","pubTime":"2025-10-31 20:00","pubTimestamp":1761912003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nTUA6S1NCM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2579543969","title":"Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2579543969","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579543969?lang=en_us&edition=fundamental","pubTime":"2025-10-31 14:14","pubTimestamp":1761891240,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics shares plunged 31.9% after-hours following the publication of Phase 1/2 trial results for its cancer therapy INT230-6.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/31/Stocks--Bonds--Market.jpeg?optimize=medium&dpr=2&auto=webp&width=120","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/31/Stocks--Bonds--Market.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/10/48550814/intensity-therapeutics-stock-cools-after-hours-following-395-surge-what-you-should-know","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/10/48550814/intensity-therapeutics-stock-cools-after-hours-following-395-surge-what-you-should-know","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4539","BK4139","INTS","LENZ","BK4007"],"gpt_icon":1},{"id":"1106798681","title":"Positive Phase 1/2 Clinical Data for Cancer Candidate Drug Sends Intensity Therapeutics (INTS.US) Soaring 395%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106798681","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106798681?lang=en_us&edition=fundamental","pubTime":"2025-10-31 08:16","pubTimestamp":1761869778,"startTime":"0","endTime":"0","summary":"Biopharmaceutical company Intensity Therapeutics (INTS.US), with a market capitalization of approximately $13 million, saw its stock surge nearly 395% at Thursday's close after announcing Phase 1/2...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4539","BK4139","INTS"],"gpt_icon":1},{"id":"2579178654","title":"BUZZ-U.S. STOCKS ON THE MOVE-Fiserv, CMS Energy, Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2579178654","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579178654?lang=en_us&edition=fundamental","pubTime":"2025-10-31 01:41","pubTimestamp":1761846118,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Fiserv, CMS Energy, ModernaEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nL6N3WB0L4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LKQ","KMB","WOLF","SNSE","MGM","SHAK","INTS","IP","HSY","CMG","FI","CLF","AME","RIOT","CAH","NAVN","BMY","CVNA","FISV","LHX","SVRA","HWM","CMCSA","EBAY","TMDX","MRNA","BIIB","FOXA","SIRI","PWR","SFM","VERU","CHRW","EXR","MRK","DOCU","CMS","EL","MNMD","MO"],"gpt_icon":1},{"id":"2579146826","title":"BUZZ-Intensity Therapeutics shares more than double on promising cancer trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2579146826","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579146826?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:01","pubTimestamp":1761825711,"startTime":"0","endTime":"0","summary":"BUZZ-Intensity Therapeutics shares more than double on promising cancer trial data** Intensity Therapeutics's shares INTS.O rocket 128.6% to $0.62 premarket** Co's experimental cancer drug, INT230-6, showed encouraging results in patients with advanced cancers, according to a study published in Lancet's eBioMedicine** INTS says INT230-6 showed 75% disease control rate in advanced cancers - eBioMedicine** Drug injected directly into tumors; shrank untreated tumors in 20% of patients, co says** Co Median survival was 11.9 months; rose to 21.3 months in sarcoma patients** Up to last close, stock was down ~85% YTD   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nL4N3WB1RW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2579487301","title":"Intensity Therapeutics Reports Promising Phase 1/2 Results for INT230-6 in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2579487301","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579487301?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:30","pubTimestamp":1761823842,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics, Inc. announced the publication of clinical results from its phase 1/2 IT-01 clinical study investigating INT230-6 for the treatment of metastatic or refractory cancers. The results, published in eBioMedicine, a Lancet Discovery Science journal, include data on disease control rate, overall survival, immune activation, and safety. The study evaluated INT230-6 administered intratumorally in adult patients with advanced solid tumors, reporting a disease control rate of 75% and a median overall survival of 11.9 months among heavily pretreated patients with over 20 types of cancer. These results were published on October 29, 2025, and will be discussed in a webinar on October 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL4KpZdF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2579314847","title":"Intensity Therapeutics, Inc. Announces Publication of Clinical Results of Int230-6 for the Treatment of Metastatic or Refractory Cancers in Ebiomedicine, a Lancet Discovery Science Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2579314847","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579314847?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:30","pubTimestamp":1761823802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUA5MHZQM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":41,"code":"91000000","status":"200"}]}}